Poseida Therapeutics is letting go of 52 employees from its San Diego location, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The layoffs will take effect Oct. 1. It is unclear if the workforce reduction is in connection with the Roche acquisition.
All entries for: Oncology
August 8, 2025
Poseida Therapeutics
Layoffs
San Diego, CA
201-500 employees
Disease Area: Hematology, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
August 8, 2025
Iovance Biotherapeutics
Layoffs
San Carlos, CA
501-1,000 employees
Months after lowering its full-year guidance, Iovance Biotherapeutics has slashed its headcount by fewer than 20%, according to an Aug. 6 report from Endpoints News, which confirmed the layoffs with a company spokesperson. “This restructuring will extend our cash runway,” the spokesperson told Endpoints, adding that the layoffs will “support [its] mission to innovate, develop and deliver” its pipeline of tumor-infiltrating lymphocyte cell therapies for patients who need them.
Disease Area: Oncology
Drug Type: Biologic
August 7, 2025
Bayer
Layoffs
Whippany, NJ
50,001+ employees
Workforce cuts continue at Bayer, with CEO Bill Anderson announcing on the company’s second-quarter earnings call on Aug. 6 that it expects more layoffs to come. These would follow the 2,000 employees it said it was letting go during first-quarter earnings and around 11,000 total since Bayer initiated a sweeping reorganization initiative in July 2023.
Disease Area: Cardiology, Hematology, Multiple, Oncology
Drug Type: Biologic, Small Molecule
August 4, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck projected it could let go of about 6,000 employees as part of a multiyear process, affecting around 8% of its global workforce, as part of its recently announced cost-cutting initiative.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 1, 2025
Moderna
Layoffs
Cambridge, MA
1,001-5,000 employees
Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company,” CEO Stéphane Bancel told employees in a note July 31.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
July 30, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
During the company’s second quarter earnings report, Merck CEO Rob Davis said that the company was undergoing a $3 billion cut in spending, spread across administrative, sales and research and development roles. The savings amount to about $1.7 billion annually, hoping to hit the $3 billion mark by 2027.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 30, 2025
GSK
Negative Outlook
London, UK
50,001+ employees
While there is currently significant uncertainty regarding the implementation of some of these reforms or the scope of amended or additional reforms, the implementation of reforms could significantly reduce net sales resulting from the Medicare programs and limit our ability to increase the prices that we charge for our drugs. Reforms or other changes to these payment systems may change the availability, methods and rates of reimbursements from Medicare, private insurers and other third-party payors for our current and any future approved products. These reforms may affect future investments in our drug development, should the reforms affect our risk-benefit analysis of investing in a drug candidate. Some of these changes and proposed changes could result in reduced reimbursement rates or the elimination of dual sources of payment, which could reduce the price that we or any of our collaborators or licensees receive for any products in the future, and which would adversely affect our business strategy, operations and financial results.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
July 29, 2025
Adaptimmune Therapeutics
Layoffs
Oxfordshire, UK
201-500 employees
U.K.-based Adaptimmune Therapeutics plans to cut 62% of its workforce once its deal to sell four cell therapy assets to US WorldMeds closes, according to an SEC filing. US WorldMeds, a specialty pharma based in Louisville, Kentucky, intends to offer employment to about half of the biotech’s workforce as part of the transaction, the filing noted.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
July 29, 2025
Roivant Sciences
Negative Outlook
New York, NY
501-1,000 employees
The impact of the IRA on research and development, the pharmaceutical supply chain and other aspects of our business and industry remains uncertain. Over time, provisions of the IRA could increase our government discount and rebate liabilities, reduce the revenues we may eventually be able to collect from sales of our products as well as present potential challenges for payor negotiations and formulary access.
Disease Area: Oncology
Drug Type: Small Molecule
July 29, 2025
Incyte Corp
Negative Outlook
Wilmington, DE
1,001-5,000 employees
While there is currently significant uncertainty regarding the implementation of some of these reforms or the scope of amended or additional reforms, the implementation of reforms could significantly reduce net sales resulting from the Medicare programs and limit our ability to increase the prices that we charge for our drugs. Reforms or other changes to these payment systems may change the availability, methods and rates of reimbursements from Medicare, private insurers and other third-party payers for our current and any future approved products. These reforms may affect future investments in our drug development, should the reforms affect our risk-benefit analysis of investing in a drug candidate. Some of these changes and proposed changes could result in reduced reimbursement rates or the elimination of dual sources of payment, which could reduce the price that we or any of our collaborators or licensees receive for any products in the future, and which would adversely affect our business strategy, operations and financial results.
Disease Area: Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
